miltefosine has been researched along with Experimental Mammary Neoplasms in 18 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, the concept of clinical trials requires new approaches to dose finding and response evaluation, because the dose-response relationship of this compound is distinctly different from that of classical cytostatic agents." | 1.30 | D-21266, a new heterocyclic alkylphospholipid with antitumour activity. ( Engel, J; Hilgard, P; Klenner, T; Kutscher, B; Nössner, G; Stekar, J, 1997) |
| " Single administration of equimolar HePC doses results in differing pharmacokinetic values for free HePC (p." | 1.29 | Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine. ( Berger, MR; Drevs, J; Eibl, H; Kaufmann-Kolle, P; Kötting, J; Marschner, N; Unger, C, 1994) |
| "The histopathological change from tubular adenocarcinoma to malignant adenoacanthoma might be caused by an overgrowth of the primary epithelial tumor cells or by a real transformation in the morphological characteristics of the tumor, which may occur during repeated transplantation." | 1.28 | Effect of miltefosine on transplanted methylnitrosourea-induced mammary carcinoma growing in Fischer 344 rats. ( Amelung, F; Berger, MR; Heyl, P; Reinhardt, M, 1992) |
| "Methylnitrosourea was used in the present study to induce autochthonous mammary carcinomas in virgin Sprague-Dawley rats." | 1.28 | Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations. ( Berger, MR; Eibl, H; Kötting, J; Unger, C, 1992) |
| " After oral application He-PC was well absorbed from the intestine and metabolized in the liver by phospholipases C and D." | 1.28 | Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. ( Breiser, A; Damenz, W; Eibl, H; Engel, J; Fleer, EA; Hilgard, P; Kim, DJ; Nagel, G; Unger, C, 1989) |
| " A dose-response relationship was seen after daily oral treatment with complete suppression of tumor growth at doses of 46." | 1.27 | Characterization of the antitumor activity of hexadecylphosphocholine (D 18506). ( Berger, MR; Eibl, H; Engel, J; Hilgard, P; Schumacher, W; Stekar, J; Unger, C; Voegeli, R, 1988) |
| " In rats, the LD50 of HPC was 606 mumol/kg; the maximum tolerable dose over four weeks was 39 mumol/kg." | 1.27 | Alkyl phosphocholines: toxicity and anticancer properties. ( Berger, MR; Eibl, HJ; Garzon, FT; Muschiol, C; Scherf, HR; Schmähl, D; Schuler, B; Unger, C; Zeller, WJ, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (22.22) | 18.7374 |
| 1990's | 14 (77.78) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaufmann-Kolle, P | 2 |
| Drevs, J | 1 |
| Berger, MR | 10 |
| Kötting, J | 2 |
| Marschner, N | 1 |
| Unger, C | 8 |
| Eibl, H | 8 |
| Stekar, J | 4 |
| Hilgard, P | 5 |
| Voegeli, R | 2 |
| Maurer, HR | 1 |
| Engel, J | 4 |
| Kutscher, B | 2 |
| Nössner, G | 2 |
| Schumacher, W | 2 |
| Betsch, B | 1 |
| Gebelein, M | 1 |
| Amtmann, E | 1 |
| Heyl, P | 2 |
| Scherf, HR | 4 |
| Klenner, T | 1 |
| Reinhardt, M | 2 |
| Amelung, F | 1 |
| Ries, UJ | 1 |
| Fleer, EA | 2 |
| Breiser, A | 2 |
| Fenneberg, K | 1 |
| Zeisig, R | 1 |
| Fichtner, I | 1 |
| Arndt, D | 1 |
| Jungmann, S | 1 |
| Yanapirut, P | 1 |
| Schmähl, D | 5 |
| Richter, H | 1 |
| Seelig, MH | 1 |
| Angres, G | 1 |
| Damenz, W | 1 |
| Kim, DJ | 1 |
| Nagel, G | 1 |
| Schuler, B | 2 |
| Muschiol, C | 1 |
| Garzon, FT | 1 |
| Zeller, WJ | 1 |
| Eibl, HJ | 1 |
1 review available for miltefosine and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Hexadecylphosphocholine: a new and selective antitumor drug.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Drug Screening Assays, Antitumor; Female; Humans; | 1990 |
17 other studies available for miltefosine and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Body Weight; Chromatography, High Pressure Liq | 1994 |
Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Cell Differentiation; Female; Ferr | 1993 |
Hexadecylphosphocholine differs from conventional cytostatic agents.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Chromatography, High Pressure Liquid; DNA, Viral; | 1993 |
Systemic administration of alkylphosphocholines. Erucylphosphocholine and liposomal hexadecylphosphocholine.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Half-Life; Injections, Intra | 1996 |
D-21266, a new heterocyclic alkylphospholipid with antitumour activity.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Body Weight; Dose-Response Relatio | 1997 |
Effect of miltefosine on transplanted methylnitrosourea-induced mammary carcinoma growing in Fischer 344 rats.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Body Weight; Female; Keratins; Ma | 1992 |
In vitro and in vivo antitumoral activity of alkylphosphonates.
Topics: Animals; Antineoplastic Agents; Cell Survival; Drug Screening Assays, Antitumor; Female; Mammary Neo | 1992 |
Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations.
Topics: Animals; Antineoplastic Agents; Cell Division; Chromatography, High Pressure Liquid; Dose-Response R | 1992 |
Antitumor effects of alkylphosphocholines in different murine tumor models: use of liposomal preparations.
Topics: Animals; Antineoplastic Agents; Hemolysis; Humans; Leukemia P388; Liposomes; Mammary Neoplasms, Expe | 1991 |
In vitro investigations on the antineoplastic effect of hexadecylphosphocholine.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Breast Neoplasms; Colony-Forming Units Assay; Hum | 1991 |
New pharmaceuticals: miltefosine.
Topics: Animals; Antineoplastic Agents; Mammary Neoplasms, Experimental; Neoplasms; Phosphorylcholine | 1990 |
New cytostatics--more activity and less toxicity.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colorectal Neoplasms; Female; Male; Mammary Neoplasm | 1990 |
Tumor heterogeneity and chemosensitivity to cyclophosphamide, vinblastine and hexadecylphosphocholine.
Topics: Animals; Antineoplastic Agents; Clone Cells; Cyclophosphamide; Drug Screening Assays, Antitumor; Fem | 1990 |
Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Choline; Drug Screening Assays, Antitumor; Female; | 1989 |
Characterization of the antitumor activity of hexadecylphosphocholine (D 18506).
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Benzopyrenes; Choline; Cyclophosphamide; Dose-Response Re | 1988 |
Therapeutic activity of ET-18-OCH3 and hexadecylphosphocholine against mammary tumors in BD-VI rats.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Choline; Dose-Response Relationship, Drug; Fem | 1987 |
Alkyl phosphocholines: toxicity and anticancer properties.
Topics: Animals; Antineoplastic Agents; Carcinoma; Choline; Dose-Response Relationship, Drug; Female; Male; | 1987 |